Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy.

Gianni GhettiMaria Claudia D'AvellaLorenzo Pradelli

Published in: ClinicoEconomics and outcomes research : CEOR (2021)

The use of cemiplimab, compared with a platinum-based chemotherapy regimen, can be considered a cost-effective option for the treatment of aCSCC patients in Italy.

Keyphrases

squamous cell carcinoma
end stage renal disease
ejection fraction
newly diagnosed
locally advanced
peritoneal dialysis
lymph node metastasis